To determine whether or not polymyxin B needs dose adjustments based on renal function by comparing the incidence of acute kidney injury (AKI) in patients whose polymyxin B doses were adjusted versus not adjusted according to renal function.
Methods:
This was a single-center, prospective study with a retrospective cohort taking place in an acute care community hospital. Forty-two patients treated with polymyxin B were evaluated between April 2012 and December 2015. The primary outcome was incidence of AKI at day 7 after initiation of polymyxin B therapy with secondary outcomes including microbiological cure, clinical cure, and 30-day mortality.
Results:
There was no difference in the incidence of AKI at day 7 in patients with polymyxin B doses adjusted according to renal function versus patients without polymyxin B dose adjustment (20.0% vs 18.2%; P = .882). There were no differences between groups in occurrence of microbiological cure, clinical cure, or 30-day mortality (27.8% vs 57.1%; P = .065, 70.0% vs 72.7%; P = .845, 40.0% vs 31.8%; P = .581, respectively).
Conclusion:
The results from this study support the use of polymyxin B without any dose adjustment in the setting of renal impairment.
EvansMEFeolaDJRappRP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Pharmacotherapy. 1999;33(9):960–967.
2.
LandmanDGeorgescuCMartinDA, et al.Polymyxins revisited. Clin Microbiol Rev. 2008;21(3):449–465.
3.
TuonFFRigattoMHLopesCK, et al.Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014;43(4):349–352.
4.
ZavasckiAPGoldaniLZLiJ, et al.Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60(6):1206–1215.
5.
LiJNationRLTurnidgeJD, et al.Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.
6.
ZavasckiAPGoldaniLZCaoGC, et al.Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47(10):1298–1304.
7.
LiJTurnidgeJMilneR, et al.In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45(3):781–785.
8.
OwenRJLiJNationRL, et al.In vitro colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007;59(3):473–477.
9.
TamVHSchillingANVoG, et al.Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49(9):3624–3630.
10.
KwaAKasiakouSKTamVH, et al.Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5(5):811–821.
11.
VardakasKFalagasM. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;49(2):233–238.
12.
KassamaliZDanzigerL. To B or not to B, that is the question: is it time to replace colisitin with polymyxin B?Pharmacotherapy. 2015;35(1):17–21.
13.
FalagasMEKasiakouSK. Toxicity of polymyxins: a systemic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27. http://ccforum.com/content/10/1/R27.
14.
FalagasMERafailidisPIIoannidouE, et al.Colisitin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35(2):194–199.
15.
PogueJMLeeJMarchaimD, et al.Incidence of and risk factors for colisitin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–884.
16.
HartzellJDNeffRAkeJ, et al.Nephrotoxicity associated with intravenous colisitin (colistmethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724–1728.
17.
OuderkirkJPNordJATurettGS, et al.Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003;47(8):2659–2662.
18.
MendesCACordeiroJABurdmannEA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother. 2009;43(12):1948–1955.
19.
OliveiraMSPradoGVCostaSF, et al.Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis. 2009;65(4):431–435.
20.
EsaianDDubrovskayaYPhillipsM, et al.Effectiveness and tolerability of polymyxin B dosing protocol. Ann Pharmacother. 2012;46(3):455–456.
21.
KubinCJEllmanTMPhadkeV, et al.Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect. 2012;65(1):80–87.
22.
PheKLeeYMcDaneldPM, et al.In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740–2746.
23.
AkajagborDWilsonSShere-WolfeK, et al.Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013;57(9):1300–1303.
24.
ZavasckiANationR. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?Antimicrob Agents Chemother. 2017;61(3):e02319–e02316.
25.
NelsonBCEirasDPGomez-SimmondsA, et al.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant gram-negative rods. Antimicrob Agents Chemother. 2015;59(11):7000–7006.
26.
SandriAMLandersdorgerCBJacobJ, et al.Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524–531.
27.
SandriAMLandersdorgerCBJacobJ, et al.Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother. 2013;68(3):674–677.
28.
HoeprichPD. The polymyxins. Med Clin North Am. 1970;54(5):1257–1265.
29.
Polymyxin B [package insert]. X-gen Pharmaceuticals Inc. Big Flats, NY: X-gen Pharmaceuticals Inc; 2015.
30.
MountfordCLeeTde LemosJ, et al.Quality and usability of common drug information databases. Can J Hosp Pharm. 2010;63(2):130–137.
31.
PolymyxinBLexiD. Wolters Kluwer Health, Inc. Hudson, OH: Lexicomp; 2016. http://online.lexi.com. Accessed March 10, 2016.
32.
PolymyxinB.Micromedex 2.0. Truven Health Analytics, Inc. Greenwood Village, CO. 2016. http://www.micromedexsolutions.com. Accessed March 10, 2016.
33.
BellomoRRoncoCKellumJA, et al.Acute kidney failure—definition, outcome measures, animal models, fluid therapy, and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204–R212.
34.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
35.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fourth Informational Supplement. Wayne, PA: Document M100-S25, Clinical and Laboratory Standards Institute; 2015.
36.
AbdelraoufKHeJLedesmaKR, et al.Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother. 2012;56(11):5724–5727.
37.
EliasLSKonzenDKrebsJM, et al.The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231–2237.
38.
TumbarelloMVialePViscoliC, et al.Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950.
39.
GarastoSFuscoSCoricaF, et al.Estimating glomerular filtration in older people. Biomed Res Int. 2014;2014:916542. doi:10.111155/2014/916542
40.
QureshiZAPatersonDLPotoskiBA, et al.Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108–2113.
41.
RigattoMHVieiraFJAntochevisLC, et al.Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2015;59(10):6575–6580.
